Citi analyst Patrick Donnelly downgraded Guardant Health to Neutral from Buy with a price target of $33, down from $60. The analyst cut its target multiple for the shares, saying Guardant deserves to trade inline with the peer group given its slowing growth and "longer line of sight" to profitability.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GH:
- Guardant Health price target lowered to $35 from $50 at Piper Sandler
- Guardant Health price target lowered to $66 from $73 at Morgan Stanley
- Guardant Health price target lowered to $50 from $60 at BTIG
- Guardant Health price target lowered to $60 from $65 at Canaccord
- Guardant Health price target lowered to $53 from $70 at Cowen
